The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Cognitive decline in Parkinson disease
Open accessAbstract
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition - or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-β 42, a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*ε4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover there are several candidate genetic risk factors that overlap for AD and PD, most notably APOE and MAPT [127].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [127]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
Self-citationLitvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., et al. (2012) · Movement Disorders · doi:10.1002/mds.24893 · Cited by 2,609
Self-citationThe Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., ADENA, M. A., Halliday, G. M., & Morris, J. G. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,346
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Healy, D. G., Falchi, M., O'Sullivan, S. S., Bonifati, V., Durr, A., Bressman, S., Brice, A., Aasly, J., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,425
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Self-citationMultimodal classification of Alzheimer's disease and mild cognitive impairment
Zhang, D., Wang, Y., Zhou, L., Yuan, H., & Shen, D. G. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.01.008 · Cited by 1,340
Cited by
Sorted by citations
Items 501–600 of 1,000
Ma, S., Zhuang, W., Wang, X., Zhang, D., Wang, H., Han, Q., Ding, Q., Li, Y., Li, W., & Li, T. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1495492 · Cited by 11
Cognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes
Hu, M. T., Querejeta, A., Rowe, J. B., Zerenner, T., Church, A., Fumi, R., Costantini, A. A., Jabbari, E., Jensen, M. T., Gerhard, A., et al. (2025) · Brain · doi:10.1093/brain/awaf132 · Cited by 12
Semantic verbal fluency: network analysis in Alzheimer’s and Parkinson’s disease
Arias‐Trejo, N., Luna-Umanzor, D. I., Angulo‐Chavira, A. Q., Ríos-Ponce, A. E., González-González, M. M., Ramírez-Díaz, J. F., Sánchez-Reyes, M., Marín-García, G., & Arias-Carrión, Ó. (2021) · Journal of Cognitive Psychology · doi:10.1080/20445911.2021.1943414 · Cited by 11
Cognitive function in men with non-motor features of Parkinson’s disease
Flores‐Torres, M. H., Hughes, K. C., Molsberry, S. A., Gao, X., Kang, J. H., Schwarzschild, M. A., & Ascherio, A. (2021) · BMJ Neurology Open · doi:10.1136/bmjno-2020-000112 · Cited by 11
Wang, J., Liu, J., Wang, Z., Gao, F., Yang, J., Wang, X.-C., Guo, Y., Wang, Y., Ma, B.-R., Wang, H., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113952 · Cited by 11
Abdullah, N. A. H., Sainik, N. Q. A. V., Esa, E., Hendri, N. A. M., Rusmili, M. R. A., Hodgson, W. C., Shaikh, M. F., & Othman, I. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.935418 · Cited by 11
Yu, Z., Pang, H., Yu, H., Wu, Z., Zhi, D., & Fan, G. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105802 · Cited by 11
Elucidating distinct molecular signatures of Lewy body dementias
Harvey, J., Pishva, E., Chouliaras, L., & Lunnon, K. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106337 · Cited by 11
Brinker, D., Śmiłowska, K., Paschen, S., Antonini, A., Moro, E., & Deuschl, G. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13962 · Cited by 11
Comparison of cognitive profile in young- and late-onset parkinson's disease patients
Joshi, D., CHAUDHARY, S. K., Pathak, A., Mishra, V., Chaurasia, R. N., & Gupta, G. (2018) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_262_17 · Cited by 11
Molecular interaction of investigational ligands with human brain acetylcholinesterase
Shakil, S. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28461 · Cited by 11
Bezdíček, O., Ballarini, T., Albrecht, F., Libon, D. J., Lamar, M., Růžička, F., Roth, J., Hurlstone, M. J., Mueller, K., Schroeter, M. L., et al. (2020) · Journal of Neuropsychology · doi:10.1111/jnp.12208 · Cited by 12
Can Nutritional Adequacy Help Evade Neurodegeneration in Older Age? A Review
Ajibawo-Aganbi, U., Saleem, S., Khan, S. Z. A., Veliginti, S., Bastidas, M. V. P., Lungba, R. M., & Cancarevic, I. (2020) · Cureus · doi:10.7759/cureus.10921 · Cited by 11
INFLUENCE OF SLEEP DISTURBANCES ON COGNITIVE DECLINE IN PATIENTS WITH PARKINSON’S DISEASE
Shkodina, A. D., Tarianyk, K. А., & Boiko, D. I. (2020) · Ukrainian Scientific Medical Youth Journal · doi:10.32345/usmyj.3(117).2020.58-67 · Cited by 11
Peptide Profile of Zebrafish Brain in a 6-OHDA-Induced Parkinson Model
Fiametti, L. O., Correa, C. N., & de Castro, L. M. (2021) · Zebrafish · doi:10.1089/zeb.2020.1945 · Cited by 11
Chung, J., Ushakova, A., Doitsidou, M., Tzoulis, C., Tysnes, O., Dalen, I., Pedersen, K. F., Alves, G. W., & Maple‐Grødem, J. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136243 · Cited by 12
Ophey, A., Wolfsgruber, S., Roeske, S., Polcher, A. A., Spottke, A. E., Frölich, L., Hüll, M., Jessen, F., Kornhuber, J., Maier, W., et al. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12223 · Cited by 11
Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson’s disease
Sampedro, F., Marín‐Lahoz, J., Martínez‐Horta, S., Pagonabarraga, J., & Kulisevsky, J. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112039 · Cited by 11
Neuropsychological profile associated with an alpha-synuclein gene (SNCA) duplication
Kielb, S., Kisanuki, Y. Y., & Dawson, E. L. (2021) · The Clinical Neuropsychologist · doi:10.1080/13854046.2021.1914735 · Cited by 11
Transcriptomic Signatures Associated With Regional Cortical Thickness Changes in Parkinson’s Disease
Keo, A., Dzyubachyk, O., van der Grond, J., van Hilten, J. J., Reinders, M. J. T., & Mahfouz, A. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733501 · Cited by 8
Fu, J., Gao, X., Lu, Y., Lü, F., Wang, Y., Chen, P., Wang, C., Yuan, C., & Liu, S. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116878 · Cited by 11
Prajjwal, P., Kolanu, N. D., Reddy, Y. B., Ahmed, A., Marsool, M. D. M., Santoshi, K., Pattani, H. H., John, J., Chandrasekar, K. K., & Hussin, O. A. (2024) · Health Science Reports · doi:10.1002/hsr2.2019 · Cited by 12
Chartier, C., Godard, J., Durand, S., Humeau‐Heurtier, A., Ménétrier, E., Allain, P., & Besnard, J. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07808-x · Cited by 10
Mitochondrial Dysfunction in Parkinson’s Disease: A Contribution to Cognitive Impairment?
Scorziello, A., Sirabella, R., Sisalli, M. J., Tufano, M., Giaccio, L., D’Apolito, E., Castellano, L., & Annunziato, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111490 · Cited by 11
Psychiatric and cognitive symptoms of Parkinson's disease: A life's tale
Amstutz, D., Sousa, M., Maradan‐Gachet, M. E., Debove, I., Lhommée, E., & Krack, P. (2024) · Revue Neurologique · doi:10.1016/j.neurol.2024.11.004 · Cited by 11
The role of Apolipoprotein E4 on cognitive impairment in Parkinson’s disease and Parkinsonisms
Rosal, A. E., Martin, S. L., & Strafella, A. P. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1515374 · Cited by 10
Zhao, Y., Cai, J., Song, J. G., Shi, H., Kong, W., Li, X., Wei, W., & Xue, X. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1575815 · Cited by 10
Disentangling the Role of Working Memory in Parkinson’s Disease
Salmi, J., Ritakallio, L., Fellman, D., Ellfolk, U., Rinne, J. O., & Laine, M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572037 · Cited by 12
Weber, J., Abeln, V., Steichele, K., Foitschik, T., & Stuckenschneider, T. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.15008 · Cited by 10
Parkinson’s Disease Detection based on Changes of Emotions during Speech
Skibińska, J., & Bürget, R. (2020) · International Congress on Ultra Modern Telecommunications and Control Systems and Workshops (ICUMT) · doi:10.1109/icumt51630.2020.9222446 · Cited by 10
Bakeberg, M. C., Gorecki, A. M., Pfaff, A. L., Hoes, M. E., Kõks, S., Akkari, P. A., Mastaglia, F. L., & Anderton, R. S. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00200-y · Cited by 10
Torres-Yaghi, Y. A., Carwin, A., Carolan, J., Nakano, S., Amjad, F., & Pagán, F. (2021) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 10
Park, S., & Schott, N. (2022) · Applied Neuropsychology Adult · doi:10.1080/23279095.2022.2147837 · Cited by 10
Santulli, C., Bon, C., Cecco, E. D., Codrich, M., Narkiewicz, J., Parisse, P., Perissinotto, F., Santoro, C., Persichetti, F., Legname, G., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05489-y · Cited by 10
Sun, M., Yan, T., Liu, R., Zhao, X., Zhou, X., Ma, Y., & Jia, J. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-1396 · Cited by 10
Brandão, P. R. D. P., Pereira, D. A., Grippe, T. C., Bispo, D. D. D. C., Maluf, F. B., Yunes, M. P., Filho, G. N., Alves, C. H. L., Pagonabarraga, J., Kulisevsky, J., et al. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13657 · Cited by 10
Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease
Flores‐Torres, M. H., Bjørnevik, K., Hung, A. Y., Healy, B. C., Schwarzschild, M. A., Blacker, D., & Ascherio, A. (2023) · Movement Disorders · doi:10.1002/mds.29503 · Cited by 12
Osuna‐Ramos, J. F., Camberos-Barraza, J., Torres-Mondragón, L. E., Rábago-Monzón, Á. R., Camacho-Zamora, A., Valdez-Flores, M. A., Angulo‐Rojo, C., Guadrón‐Llanos, A. M., Picos-Cárdenas, V. J., Calderón-Zamora, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417458 · Cited by 13
Olubodun-Obadun, T. G., Ishola, I. O., Folarin, O. R., Oladoja, F. A., Gilbert, T. T., Aniekwensi, I. M., Bisiriyu, A., Joseph-Iwebi, N. A., Adebanjo, F. O., Olopade, J. O., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117623 · Cited by 10
Li, X., Pang, H., Bu, S., Zhao, M., Wang, J., Liu, Y., Hong-mei, Y., & Fan, G. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106578 · Cited by 10
Cao, G., Wang, X., Li, K.-K., Zhao, A.-H., Shen, L., & Yu, D. (2018) · Phytochemistry Letters · doi:10.1016/j.phytol.2018.05.016 · Cited by 10
Tian, T., Yao, Y., Yang, B., Zhang, K., & Liu, B. (2019) · Chemical Communications · doi:10.1039/c9cc00131j · Cited by 10
Genetic architecture of neurodegenerative dementias
Clarimón, J., Moreno–Grau, S., Cervera‐Carles, L., Dols‐Icardo, O., Sánchez‐Juan, P., & Ruiz, A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108014 · Cited by 11
Li, Z., Liu, C., Wang, Q., Liang, K., Han, C., Qiao, H., Zhang, J., & Meng, F. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.715455 · Cited by 10
Shkodina, A. D., Iengalychev, T., Tarianyk, K. А., Boiko, D. I., Lytvynenko, N., & Skrypnikov, A. M. (2021) · AFMN Biomedicine · doi:10.5937/afmnai39-33652 · Cited by 10
Cao, F., Guan, X., Ma, Y., Shao, Y., & Zhong, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.554660 · Cited by 10
Zhu, S.-G., Chen, Z.-L., Xiao, K., Wang, Z., Wenbin, L., Liu, R., Huang, S., Zhu, J., Zhang, X., & Wang, J. (2024) · European journal of medical research · doi:10.1186/s40001-024-01924-2 · Cited by 10
Chen, L., Lu, H., Mao, L., Lin, J., & Liu, P. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39194 · Cited by 9
Mohammadi, R., Ng, S. Y., Tan, J. Y., Ng, A. S. L., Deng, X., Choi, X., Heng, D. L., Neo, S., Xu, Z., Tay, K. Y., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12122758 · Cited by 9
Highlighting the Protective or Degenerative Role of AMPK Activators in Dementia Experimental Models
Nikbakhtzadeh, M., Shaerzadeh, F., & Ashabi, G. (2021) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527320666210526160214 · Cited by 9
Gómez‐Soria, I., la Cruz, N. B., Cuenca‐Zaldívar, J. N., Calvo, S., Herrero, P., & Calatayud, E. (2021) · Clinical Gerontologist · doi:10.1080/07317115.2021.1937764 · Cited by 12
Brak, I. V., Filimonova, E., Zakhariya, O., Khasanov, R., & Stepanyan, I. V. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.781488 · Cited by 13
Pamlényi, K., Regdon, G., Jójárt‐Laczkovich, O., Nemes, D., Bácskay, I., & Kristó, K. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106491 · Cited by 9
Proxy-analysis of the genetics of cognitive decline in Parkinson’s disease through polygenic scores
Faouzi, J., Tan, M. M. X., Casse, F., Lesage, S., Tesson, C., Brice, A., Mangone, G., Mariani, L., Iwaki, H., Olivier Colliot, A., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-023-00619-5 · Cited by 9
Creese, B., Albertyn, C. P., Dworkin, S., Thomas, R. S., Wan, Y.-M., & Ballard, C. G. (2018) · Journal of Neuropsychology · doi:10.1111/jnp.12169 · Cited by 9
Self-citationCognitive Impairment in Parkinson’s Disease: What We Know so Far
Painous, C., & Martı́, M. J. (2020) · Research and Reviews in Parkinsonism · doi:10.2147/jprls.s263041 · Cited by 9
Tang, H., Xu, Y., Liu, L., He, L., Huang, J., Pan, J., He, W., Wang, Y., Yang, X., Hou, X., et al. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.09.057 · Cited by 9
Daniels, C., Steigerwald, F., Capetian, P., Matthies, C., Malzahn, U., Heuschmann, P. U., & Volkmann, J. (2020) · Neurological Research and Practice · doi:10.1186/s42466-020-00086-w · Cited by 9
Cognitive impairment and its neuroimaging correlates in spinocerebellar ataxia 2
Stezin, A., Bhardwaj, S., Hegde, S., Jain, S., Bharath, R. D., Saini, J. S., & Pal, P. K. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.02.028 · Cited by 9
Patten, R. V., Mahmood, Z., Pickell, D., Maye, J. E., Roesch, S. C., Twamley, E. W., Filoteo, J. V., & Schiehser, D. M. (2021) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acab037 · Cited by 9
Brain Surface Area Alterations Correlate With Gait Impairments in Parkinson’s Disease
Wei, X., Wang, Z., Zhang, M., Li, M., Chen, Y., Lv, H., Tuo, H., Yang, Z., Wang, Z., & Ba, F. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.806026 · Cited by 9
Delgado‐Alvarado, M., Dacosta‐Aguayo, R., Navalpotro‐Gómez, I., Gago, B., Gorostidi, A., Jiménez‐Urbieta, H., Quiroga‐Varela, A., Ruiz‐Martínez, J., Bergareche, A., & Rodríguez‐Oroz, M. (2018) · Movement Disorders · doi:10.1002/mds.27518 · Cited by 9
Guo, Y., Ma, Z., Ning, X., Chen, Y., Tian, C., Wang, X., Zhang, Z., & Liu, J. (2021) · Molecules · doi:10.3390/molecules26175371 · Cited by 9
Gottlieb, A., Kimel-Naor, S., Zeilig, G., Beeri, M. S., & Plotnik, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-71618-6 · Cited by 8
Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson’s disease
Gu, L., Zhang, P., Gao, R., Shu, H., & Wang, P. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1465016 · Cited by 8
Managing cognitive impairment in Parkinson’s disease: an update of the literature
Goldman, J. G., Jagota, P., & Matar, E. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2450668 · Cited by 8
Tong, S., Wang, R., Li, H., Zhu, T., Geng, D., Zhang, X., & Ren, C. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111272 · Cited by 8
Aboelzahab, Y. H., Bojmehrani, A., Ahmed, Y. E., Boon, H. S., Marras, C., & Foty, R. G. (2025) · PLoS ONE · doi:10.1371/journal.pone.0319576 · Cited by 8
Camera, V., Messina, S., Tamanti, A., Bontempi, P., Petralia, L. S., Griffanti, L., Pitteri, M., Guandalini, M., Pizzini, F. B., DeLuca, G. C., et al. (2025) · Neurology Open Access · doi:10.1212/wn9.0000000000000013 · Cited by 12
Wu, J., Jin, H., Shao, Y., Mao, C., Chen, J., & Liu, C. (2021) · Brain and Behavior · doi:10.1002/brb3.2252 · Cited by 8
Manchinu, M. F., Pala, M., Palmas, M. F., Diana, M. A., Maschio, A., Etzi, M., Pisanu, A., Diana, F. I., Marongiu, J., Mansueto, S., et al. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114651 · Cited by 9
Murakami, T., Abe, M., Tiksnadi, A., Nemoto, A., Futamura, M., Yamakuni, R., Kubo, H., Kobayashi, N., Ito, H., Hanajima, R., et al. (2024) · Clinical Neurophysiology · doi:10.1016/j.clinph.2023.12.131 · Cited by 8
Validation of the Italian version of the Parkinson’s Disease- Cognitive Functional Rating Scale
Garon, M., Weis, L., Siquier, A., Fiorenzato, E., Pistonesi, F., Cianci, V., Canesi, M., Pesce, F., Reali, E., Pozzi, B., et al. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02746-6 · Cited by 8
Exclusion of older patients from randomized clinical trials in Parkinson’s disease
Kłosowska, D., Fiszer, U., Dulski, J., Górski, A., & Borysowski, J. (2024) · GeroScience · doi:10.1007/s11357-024-01104-4 · Cited by 8
Wakawa, I. A., Musami, U. B., Kwairanga, S. H., Ogualili, P. N., Mahmood, M. Y., Fugu, M. A., Gimba, M. M., Allamin, M. M., Abbas, Z. U., Sunkani, M. K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14538 · Cited by 14
Dementia with Lewy Bodies and Parkinson's Disease-Dementia: Current Perspectives
Jellinger Kurt, A. (2018) · International Journal of Neurology and Neurotherapy · doi:10.23937/2378-3001/1410076 · Cited by 8
Sarıcaoğlu, M., Yılmaz, N. H., Özer, F. F., & Hanoğlu, L. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02462-6 · Cited by 8
Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson’s disease
Oikonomou, P., van Wamelen, D. J., Weintraub, D. A., Aarsland, D., Ffytche, D. H., Martínez‐Martín, P., Rodríguez‐Blázquez, C., Leta, V., Borley, C., Sportelli, C., et al. (2021) · Brain and Behavior · doi:10.1002/brb3.2086 · Cited by 8
Self-citationKeo, A., Dzyubachyk, O., van der Grond, J., Hafkemeijer, A., van de Berg, W. D. J., van Hilten, J. J., Reinders, M. J. T., & Mahfouz, A. E. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15216 · Cited by 8
A Psychometric Tool for Evaluating Executive Functions in Parkinson’s Disease
Borgnis, F., Baglio, F., Pedroli, E., Rossetto, F., Meloni, M., Riva, G., & Cipresso, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051153 · Cited by 9
de Meneses, F. G. A., Teles, A. S., Nunes, M. K. G., Farias, D. D. S., & Teixeira, S. S. (2022) · Brain Topography · doi:10.1007/s10548-022-00901-4 · Cited by 10
Weerasinghe-Mudiyanselage, P. D. E., Kang, S., Kim, J., & Moon, C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666221005090126 · Cited by 8
Zhang, C., Yuan, Y., Sang, T., Yu, L., Yu, Y. H., Liu, X., Zhou, W., Zeng, Q., Wang, J., Peng, G., et al. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25179 · Cited by 8
Qiao, J., & Mao, Y. (2020) · Invertebrate Neuroscience · doi:10.1007/s10158-020-00244-4 · Cited by 8
Respiratory Responses to Two Voice Interventions for Parkinson's Disease
Richardson, K., Huber, J. E., Kiefer, B., Kane, C., & Snyder, S. (2022) · Journal of Speech, Language, and Hearing Research · doi:10.1044/2022_jslhr-22-00262 · Cited by 7
Four questions to predict cognitive decline in de novo Parkinson’s disease
Hlavnička, J., Mana, J., Bezdíček, O., Čihák, M., Havlík, F., Skrabal, D., Bartošová, T., Šonka, K., Růžička, E., & Dušek, P. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00958-5 · Cited by 8
Xiao, H., He, X., Zhou, W. J., Guo, X., Cai, X., & Tan, L. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1591605 · Cited by 7
Tropea, T. F., Stevenson, P. A., Flitter, M. L., Meehan, D., Morris, A., Lu, M., Iaccarino, L., Collins, E. C., Hodsdon, M. E., Irwin, D. J., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78201 · Cited by 8
Self-citationNervonic Acid Ameliorates Motor Disorder in Mice with Parkinson’s Disease
Hu, D., Cui, Y., & Zhang, J. (2021) · Neurochemical Journal · doi:10.1134/s1819712421030065 · Cited by 7
Jeyabalan, J. B., Palathoti, N., Dhanasekaran, M., Sivasamy, R., Ponnusankar, S., Dhanabal, S. P., Sankar, V., & Justin, A. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06684-1 · Cited by 7
Cognitive Impairment in Neurodegenerative Movement Disorders
Ruiz, C. A., & Poston, K. L. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1764204 · Cited by 7
Wang, J., Yang, M., Tian, Y., Feng, R., Xu, K., Teng, M., Wang, J., Wang, Q., & Xu, P. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1253791 · Cited by 7
Soto, I., McManus, R., Navarrete, W., Kasanga, E. A., Doshier, K., Nejtek, V. A., & Salvatore, M. F. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114771 · Cited by 8
PINK1 knockout rats show premotor cognitive deficits measured through a complex maze
Soto, I., Nejtek, V. A., Siderovski, D. P., & Salvatore, M. F. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1390215 · Cited by 7
Foreman, R. P., Donahue, E. K., Duran, J. J., Schiehser, D. M., Petkus, A. J., O’Neill, J., Holschneider, D. P., Choupan, J., Horn, J. D. V., Bayram, E., et al. (2024) · Brain and Behavior · doi:10.1002/brb3.3607 · Cited by 7
Oppermann, J., Tschentscher, V., Welzel, J., Geritz, J., Hansen, C., Gold, R., Maetzler, W., Scherbaum, R., & Tönges, L. (2024) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864241277157 · Cited by 8
Ye, Q., Lin, C., Xiao, F., Jiang, T., Hou, J., Zheng, Y., Xu, J., Huang, J., Chen, K., Cai, J., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1504733 · Cited by 8
Cognitive deficits in Parkinson’s disease: current perspectives
Cosgrove, J., & Alty, J. (2018) · Journal of Parkinsonism and Restless Legs Syndrome · doi:10.2147/jprls.s125064 · Cited by 10
Cognitive Problems in Parkinson Disease: Perspectives and Priorities of Patients and Care Partners
Raein, K. L., Ortiz-Hernández, S., & Benge, J. F. (2019) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000184 · Cited by 7
Pharmacology of Acetylcholine and Cholinergic Receptors
Kokaz, S. F., Deb, P. K., Abed, S. N., Al-Aboudi, A. F., Das, N., Younes, F. A., Salou, R. A., Bataineh, Y. A., Venugopala, K. N., & Mailavaram, R. P. (2020) · Springer eBooks · doi:10.1007/978-981-15-3556-7_3 · Cited by 7
Metadata
- Authors
- Aarsland, D., Creese, B., Politis, M., Chaudhuri, K. R., ffytche, D. H., Weintraub, D., & Ballard, C.
- Affiliations
- King's College London (GB)
- Corresponding author
- Aarsland, Dag
- Venue
- Nature Reviews Neurology
- Published
- 2017-03-03
- Volume
- 13
- Issue
- 4
- Pages
- 217-231
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC5643027
- OpenAlex
- W2593272776
- Cited by
- 1,027
- References
- 216
- Citations by year
- 2026: 102 · 2025: 99 · 2024: 138 · 2023: 104 · 2022: 105 · 2021: 171 · 2020: 116 · 2019: 89 · 2018: 68 · 2017: 33
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Open Research Exeter (University of Exeter) (acceptedVersion)
- Figshare (submittedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- South London and Maudsley NHS Foundation Trust
- National Institute for Health and Care Research
- King's College London
- Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- National Institute of Neurological Disorders and Stroke (P50NS053488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Parkinson's disease, cognitive decline, Parkinson's disease dementia, mild cognitive impairment, cerebrospinal fluid biomarkers, amyloid-beta 42, Lewy body pathology, APOE ε4, GBA mutations, cognitive training, nootropic drugs
- MeSH terms
- Dementia, Humans, Parkinson Disease, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
